Huntington National Bank Sells 1,210 Shares of Humana Inc. (NYSE:HUM)

Huntington National Bank lessened its holdings in Humana Inc. (NYSE:HUM) by 16.2% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,249 shares of the insurance provider’s stock after selling 1,210 shares during the quarter. Huntington National Bank’s holdings in Humana were worth $1,585,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. FPC Investment Advisory Inc. purchased a new stake in Humana in the 4th quarter valued at about $27,000. Centricity Wealth Management LLC purchased a new stake in shares of Humana in the fourth quarter valued at approximately $30,000. LFA Lugano Financial Advisors SA grew its stake in Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares in the last quarter. OFI Invest Asset Management bought a new position in Humana in the fourth quarter worth approximately $33,000. Finally, Atwood & Palmer Inc. increased its holdings in Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after purchasing an additional 60 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on HUM shares. Piper Sandler upped their price objective on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. StockNews.com cut shares of Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, March 18th. Morgan Stanley cut their price objective on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. Cantor Fitzgerald reissued a “neutral” rating and issued a $290.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Finally, JPMorgan Chase & Co. dropped their target price on Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 18th. Eighteen investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Humana presently has an average rating of “Hold” and an average price target of $280.17.

Humana Trading Down 0.4 %

NYSE:HUM opened at $264.67 on Friday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The stock’s 50 day moving average price is $268.40 and its 200 day moving average price is $272.56. The company has a market capitalization of $31.94 billion, a PE ratio of 26.60, a P/E/G ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, research analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.34%. The ex-dividend date is Friday, March 28th. Humana’s payout ratio is 35.58%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.